Do you switch therapy to sacituzumab in a patient with metastatic HR+ HER2- breast cancer who has stable systemic disease but new <1cm brain metastasis?
Answer from: Medical Oncologist at Academic Institution
Not necessarily. Particularly, if this is the first CNS lesion that was detected and the patient was able to get definitive SRS therapy. In the ABC 5 guidelines for HER2+ CNS only progression, the committee did not endorse routinely changing therapy after local treatment. A similar argument could be...
Sign in or Register to read more